Case 2: Low-Volume Recurrent mCSPC

Author(s):

Bryan Mehlhaff, MD,Scott B. Sellinger, MD

Panelists discuss how the management of low-volume recurrent metastatic castration-sensitive prostate cancer (mCSPC) focuses on personalized treatment strategies, including the use of androgen deprivation therapy and targeted therapies, to achieve optimal outcomes while minimizing treatment-related toxicity.

EP: 1.Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Overview

EP: 2.Case 1: Metastatic Castration- Sensitive Prostate Cancer (mCSPC)

Now Viewing

EP: 3.Case 2: Low-Volume Recurrent mCSPC

EP: 4.Case 3: Nonmetastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence

EP: 5.Case 4: Metastatic Castration-Resistant Prostate Cancer With an HRR Alteration

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!